GSK Enters Agreement to Acquire Nuvalent Inc.
June 10, 2026
June 10, 2026
LONDON, England, June 10 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on June 9, 2026:
* * *
GSK enters agreement to acquire Nuvalent, Inc.
- Multi-product oncology deal for assets that have validated targets and aim to address efficacy and/or tolerability limitations of existing therapies
- Includes two late-stage, potential best-in-class ROS1 (zidesamtinib) and ALK (neladalkib) inhibitors f . . .
* * *
GSK enters agreement to acquire Nuvalent, Inc.
- Multi-product oncology deal for assets that have validated targets and aim to address efficacy and/or tolerability limitations of existing therapies
- Includes two late-stage, potential best-in-class ROS1 (zidesamtinib) and ALK (neladalkib) inhibitors f . . .